Recent data has shown that hormone therapy (HT) increases the risk of cardiovascular and thromboembolic disease, particularly in users of oral HT. Phytoestrogens are popular alternatives to oestrogen therapy; however, their effects on cardiovascular risk are unknown. We investigated the effect of the phytoestrogen, genistein on the expression of genes and proteins from the haemostatic system in the liver in an ovariectomised rat model. Fifty-nine virgin female Sprague-Dawley rats were fed with soy-free chow supplemented with 17β estradiol (E2) (daily uptake 0.19 or 0.75 mg/kg body weight), or genistein (daily up-take 6 or 60 mg/kg body weight), for three months and compared to soy-free control rats. Gene expression of prothrombin, factor VII, fibrinogen alpha and fibrinogen beta was increased with E2 and genistein compared to the soy-free control group (p<0.001). Genistein increased factor VII significantly more than E2 (p<0.005). Plasminogen mRNA was increased in both treatment groups compared to the soy-free control, with genistein expression significantly higher than E2 (p<0.001). Tissue plasminogen inhibitor (tPA), plasminogen activator inhibitor-1 (PAI-1) and C-reactive protein (CRP) expression were also increased in both groups relative the soy-free control. Results of protein analysis largely concurred with those of the mRNA. Oestrogen receptor β (ERβ) was undetected while oestrogen receptor α (ERα) was detected in each sample group. Genistein can increase the expression of coagulation and fibrinolytic genes. This effect was similar and in some cases higher than 17β estradiol. These results suggest that genistein may not be neutral with respect to the haemostatic system.
1 European Heart Network European Cardiovascular Disease statistics. [Press publication] 2008 [cited December 1, 2009]; Available from: www.ehnheart.org
2
Rossouw JE,
Anderson GL,
Prentice RL.
et al.
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. J Am Med Assoc 2002; 288: 321-333.
3
Hsia J,
Langer RD,
Manson JE.
et al.
Conjugated Equine Estrogens and Coronary Heart Disease: The Women’s Health Initiative. Arch Intern Med 2006; 166: 357-365.
4
Hulley S,
Furberg C,
Barrett-Connor E.
et al.
Noncardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). J Am Med Assoc 2002; 288: 58-64.
5
Hulley S,
Grady D,
Bush T.
et al.
Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. J Am Med Assoc 1998; 280: 605-613.
8
Atteritano M,
Marini H,
Minutoli L.
et al.
Effects of the phytoestrogen genistein on some predictors of cardiovascular risk in osteopenic, postmenopausal women: a two-year randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2007; 92: 3068-3075.
9
Sacks FM,
Lichtenstein A,
Van Horn L.
et al.
Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation 2006; 113: 1034-1044.
11
Scarabin PY,
Alhenc-Gelas M,
Plu-Bureau G.
et al.
Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in post-menopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997; 17: 3071-3078.
12
Rios DRA,
Rodrigues ET,
Cardoso APZ.
et al.
Effects of isoflavones on the coagulation and fibrinolytic system of postmenopausal women. Nutrition 2008; 24: 120-126.
13
Teede HJ,
Dalais FS,
Kotsopoulos D.
et al.
Dietary soy containing phytoestrogens does not activate the hemostatic system in postmenopausal women. J Clin Endocrinol Metab 2005; 90: 1936-1941.
15
Chu MC,
Cushman M,
Solomon R.
et al.
Metabolic syndrome in postmenopausal women: the influence of oral or transdermal estradiol on inflammation and coagulation markers. Am J Obstet Gynecol 2008; 199: 526e1-7.
16
Kuiper GG,
Lemmen JG,
Carlsson B.
et al.
Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998; 139: 4252-4263.
17
Dijsselbloem N,
Vanden Berghe W,
De Naeyer A.
et al.
Soy isoflavone phyto-pharmaceuticals in interleukin-6 affections. Multi-purpose nutraceuticals at the crossroad of hormone replacement, anti-cancer and anti-inflammatory therapy. Biochem Pharmacol 2004; 68: 1171-1185.
18
Seidlova-Wuttke D,
Hesse O,
Jarry H.
et al.
Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol-17beta. Eur J Endocrinol 2003; 149: 351-362.
19
Seidlova-Wuttke D,
Jarry H,
Wuttke W.
Pure estrogenic effect of benzophenone-2 (BP2) but not of bisphenol A (BPA) and dibutylphtalate (DBP) in uterus, vagina and bone. Toxicology 2004; 205: 103-112.
20
Doerge DR,
Chang HC.
Inactivation of thyroid peroxidase by soy isoflavones, in vitro and in vivo. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 777: 269-279.
22
Lowe GD,
Upton MN,
Rumley A.
et al.
Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein--a cross-sectional population survey. Thromb Haemost 2001; 86: 550-556.
23
Hellgren M,
Conard J,
Norris L.
et al.
Cardiovascular risk markers during treatment with estradiol and trimegestone or dydrogesterone. Maturitas 2009; 62: 287-293.
24
Ghaddar HM,
Folsom AR,
Aleksic N.
et al.
Correlation of factor VIIa values with factor VII gene polymorphism, fasting and postprandial triglyceride levels, and subclinical carotid atherosclerosis. Circulation 1998; 98: 2815-2821.
28
Norris LA,
Brosnan J,
Bonnar J.
et al.
Inhibitors and activation markers of the haemostatic system during hormone therapy: a comparative study of oral estradiol (2 mg)/ dydrogesterone and estradiol (2 mg)/ trimegestone. Thromb Haemost 2008; 100: 253-260.
29
Stevenson JC,
Oladipo A,
Manassiev N.
et al.
Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers. Br J Haematol 2004; 124: 802-808.
33
Decensi A,
Omodei U,
Robertson C.
et al.
Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation 2002; 106: 1224-1228.
34
Shifren JL,
Rifai N,
Desindes S.
et al.
A comparison of the short-term effects of oral conjugated equine estrogens versus transdermal estradiol on C-reactive protein, other serum markers of inflammation, and other hepatic proteins in naturally menopausal women. J Clin Endocrinol Metab 2008; 93: 1702-1710.
35
Rachon D,
Suchecka-Rachon K,
Hak L.
et al.
Effects of intranasal 17beta-estradiol administration on serum bioactive interleukin-6 and C-reactive protein levels in healthy postmenopausal women. Menopause 2006; 13: 840-845.
36
McCarty MF.
Isoflavones made simple – Genistein’s agonist activity for the beta-type estrogen receptor mediates their health benefits. Medical Hypotheses 2006; 66: 1093-1114.
37
Altavilla D,
Crisafulli A,
Marini H.
et al.
Cardiovascular effects of the phytoestrogen genistein. Curr Med Chem Cardiovasc Hematol Agents 2004; 2: 179-186.
